Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy

医学 内科学 累积发病率 回顾性队列研究 肉毒毒素 队列 外科
作者
Uwe Walter,Christopher Mühlenhoff,Reiner Benecke,Dirk Dressler,Eilhard Mix,Janes Alt,Matthias Wittstock,Aleš Dudešek,Alexander Storch,Christoph Kamm
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:94 (20) 被引量:40
标识
DOI:10.1212/wnl.0000000000009444
摘要

Objective

To investigate the risk factors of neutralizing antibody (NAB)–induced complete secondary treatment failure (cSTF) during long-term botulinum neurotoxin (BoNT) treatment in various neurologic indications.

Methods

This monocenter retrospective cohort study analyzed the data of 471 patients started on BoNT therapy between 1995 and 2015. Blood samples of 173 patients were investigated for NABs using the mouse hemidiaphragm test (93 with suspected therapy failure, 80 prospective study participants). The frequency of NAB-cSTF was assessed for various indications: hemifacial spasm, blepharospasm, cervical dystonia, other dystonia, and spasticity. A priori defined potential risk factors for NAB-cSTF were evaluated, and a stepwise binary logistic regression analysis was performed to identify independent risk factors.

Results

Treatment duration was 9.8 ± 6.2 years (range, 0.5–30 years; adherence, 70.6%) and number of treatment cycles 31.2 ± 22.5 (3–112). Twenty-eight of 471 patients (5.9%) had NAB-cSTF at earliest after 3 and at latest after 103 treatment cycles. None of the 49 patients treated exclusively with incobotulinumtoxinA over 8.4 ± 4.2 (1–14) years developed NAB-cSTF. Independent risk factors for NAB-cSTF were high BoNT dose per treatment, switching between onabotulinumtoxinA and other BoNT formulations (except for switching to incobotulinumtoxinA), and treatment of neck muscles.

Conclusions

We present a follow-up study with the longest duration to date on the incidence of NAB-cSTF in patients treated with various BoNT formulations, including incobotulinumtoxinA. Whereas the overall risk of NAB-cSTF is low across indications and BoNT formulations, our findings underpin the recommendations to use the lowest possible dose particularly in cervical dystonia, and to avoid unnecessary switching between different formulations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大橙子发布了新的文献求助10
刚刚
舒适的天奇完成签到 ,获得积分10
1秒前
2秒前
4秒前
都是小儿卡通书完成签到,获得积分10
5秒前
6秒前
陶醉的又夏完成签到 ,获得积分10
6秒前
lily完成签到 ,获得积分10
9秒前
10秒前
子苓完成签到 ,获得积分10
12秒前
Jun完成签到 ,获得积分10
12秒前
phil完成签到,获得积分10
13秒前
祁乐安发布了新的文献求助20
13秒前
如初完成签到,获得积分10
14秒前
zzuwxj完成签到,获得积分10
17秒前
糊涂的语兰完成签到,获得积分10
21秒前
多余完成签到,获得积分10
22秒前
喝酸奶不舔盖完成签到 ,获得积分10
22秒前
朴实初夏完成签到 ,获得积分10
23秒前
23秒前
华仔应助查查make采纳,获得10
28秒前
乐乐应助普鲁卡因采纳,获得10
28秒前
美海与鱼完成签到,获得积分10
28秒前
哦豁完成签到 ,获得积分10
29秒前
阿钱小钱完成签到 ,获得积分10
30秒前
世上僅有的榮光之路完成签到,获得积分0
30秒前
能干的蜗牛完成签到,获得积分10
31秒前
芽衣完成签到 ,获得积分10
34秒前
35秒前
英姑应助大橙子采纳,获得10
38秒前
普鲁卡因发布了新的文献求助10
40秒前
积极的帽子完成签到 ,获得积分10
40秒前
量子星尘发布了新的文献求助10
42秒前
现代冷松完成签到,获得积分10
45秒前
Chimmy完成签到,获得积分10
50秒前
朴树朋友完成签到,获得积分20
50秒前
wlnhyF完成签到,获得积分10
52秒前
pursuit完成签到,获得积分10
55秒前
Neltharion完成签到,获得积分10
56秒前
沈海完成签到,获得积分10
58秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022